Patient outcomes and healthcare utilisation following implementation of an advanced therapy care pathway for inflammatory bowel disease: a multicentre, prospective quasi-experimental preimplementation/postimplementation study in the Netherlands - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating Patient Outcomes and Healthcare Utilization After the Introduction of an Advanced Therapy Care Pathway for Inflammatory Bowel Disease: A Multicenter, Prospective Quasi-Experimental Study in the Netherlands

  • By

  • Elyke H Visser

  • Martijn A Oude Voshaar

  • Reinier C A Van Linschoten

  • Jildou Hoekstra

  • Kristin Robbers

  • Vincent de Jonge

  • Edith Koehler

  • K Evelyne Verweij

  • Sanne van der Wiel

  • Daniëlle van der Horst

  • C Janneke van der Woude

  • Desiree van Noord

  • Rachel L West

  • on behalf of the Southwest Netherlands IBD Study Group

  • October 1, 2026

Share

Clinical Scorecard: Evaluating Patient Outcomes and Healthcare Utilization After the Introduction of an Advanced Therapy Care Pathway for Inflammatory Bowel Disease: A Multicenter, Prospective Quasi-Experimental Study in the Netherlands

At a Glance

CategoryDetail
ConditionInflammatory Bowel Disease (IBD)
Key MechanismsAdvanced therapy care pathway (ACP) standardizing treatment and monitoring
Target PopulationPatients with IBD receiving advanced therapies
Care SettingMulticenter healthcare facilities in the Netherlands

Key Highlights

  • 1173 patients included, median age 45 years, 55% female
  • 64% of cases were Crohn's disease
  • Significant reduction in hospital admissions post-ACP implementation
  • Disease control remained unchanged after ACP implementation
  • ACP aims to standardize treatment and reduce healthcare utilization

Guideline-Based Recommendations

Diagnosis

  • Utilize electronic medical records and validated questionnaires for outcome assessment

Management

  • Implement advanced therapy care pathways to standardize treatment for IBD

Monitoring & Follow-up

  • Regularly assess patient outcomes and healthcare utilization metrics

Risks

  • Potential for treatment variation if care pathways are not followed

Patient & Prescribing Data

Individuals with inflammatory bowel disease receiving biologics or small molecules

ACP defined minimum care requirements without compromising disease control

Clinical Best Practices

  • Adopt structured care pathways to enhance quality of care
  • Monitor healthcare utilization to assess the impact of care pathways
  • Encourage collaboration among healthcare providers to reduce treatment variation

Related Resources & Content

Original Source(s)

Patient outcomes and healthcare utilisation following implementation of an advanced therapy care pathway for inflammatory bowel disease: a multicentre, prospective quasi-experimental preimplementation/postimplementation study in the Netherlands

  • by Elyke H Visser, Martijn A Oude Voshaar, Reinier C A Van Linschoten, Jildou Hoekstra, Kristin Robbers, Vincent de Jonge, Edith Koehler, K Evelyne Verweij, Sanne van der Wiel, Daniëlle van der Horst, C Janneke van der Woude, Desiree van Noord, Rachel L West, on behalf of the Southwest Netherlands IBD Study Group

  • October 1, 2026

Related Content

Risk of Infections With Infliximab vs Adalimumab Among Children With Inflammatory Bowel Disease

NIH researchers identify regulatory cells that shield against inflammatory bowel disease

  • June 8, 2026

Equitable access to inflammatory bowel disease care: challenges, strategies, and future directions